title: Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial.
authors.forename: Bertram
authors.initials: B
authors.lastname: Pitt
authors.forename: Mihai
authors.initials: M
authors.lastname: Gheorghiade
mesh_terms: D000450:Aldosterone / Q000096:biosynthesis*; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D017483:Receptors, Vasopressin / Q000378:metabolism; D000077602:Tolvaptan; D017211:Treatment Failure
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D017483:Receptors, Vasopressin; D000077602:Tolvaptan; D000450:Aldosterone